Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma

Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma: a Prospective Single-center Cross-sectional Case-control Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The glycocalyx is a fibrillary lining structure that covers the inner surface of blood vessels. Composed of glycoproteins and polysaccharides, it is an essential determinant of vascular endothelial physiology: it limits coagulation activation and adapts capillary perfusion. Studies have shown glycocalyx alteration in various vascular and autoimmune pathologies such as diabetes, high blood pressure, chronic renal failure, ischemic heart disease, stroke, dementia, septic shock, and several other inflammatory pathologies with a common basis in vascular insufficiency. Glaucoma is a progressive, chronic and asymptomatic optic neuropathy characterized by visual field damage and abnormalities of the optic nerve head. Two hypotheses have been proposed as a basis for this progressive damage: * the mechanical theory, which explains the papillary excavation by a compression of the optic nerve head under the effect of high intraocular pressure; and * the ischemic theory, explained by a circulatory insufficiency at the level of the blood capillaries of the retina and especially of the optic nerve head. This latter theory is related to several pathologies that have circulatory insufficiency as common underlying pathophysiology, and in which damage to the glycocalyx has been well studied. Glycocalyx damage has rarely been studied in glaucoma. Yang et al. showed that the glycocalyx, present in Schlem's canal, plays a major role in the transduction of shear stress and regulation of outflow resistance to the aqueous humor, which may constitute an interesting biomarker for glaucomatous pathologies.

Who May Be Eligible (Plain English)

Who May Qualify: - Express consent to participate in the study - Only for case group: primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes - Only for control group: Absence optic nerve pathology (including primary open angle glaucoma) Who Should NOT Join This Trial: - Pregnant or breastfeeding woman - Sleep apnea - Renal insufficiency - Parkinson's disease - Alzheimer's disease - Antiphospholipid syndrome - Cancer for which treatment ended less than 2 years ago - Stroke less than 1 year ago - Myocardial infarction less than 1 year ago Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Express consent to participate in the study * Only for case group: primary open angle glaucoma (defined as the presence of visual field damage attributed to glaucomatous optic neuropathy) in both eyes * Only for control group: Absence optic nerve pathology (including primary open angle glaucoma) Exclusion Criteria: * Pregnant or breastfeeding woman * Sleep apnea * Renal insufficiency * Parkinson's disease * Alzheimer's disease * Antiphospholipid syndrome * Cancer for which treatment ended less than 2 years ago * Stroke less than 1 year ago * Myocardial infarction less than 1 year ago

Treatments Being Tested

PROCEDURE

Glycocheck

Assessment of the sublingual microvascularization

PROCEDURE

Ophthalmological examinations

Description : Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)

Locations (1)

Hôpital Fondation A. de Rothschild
Paris, France